Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update
by Jessica Moore · The Cerbat GemPharming Group N.V. Sponsored ADR (NASDAQ:PHAR – Get Free Report) was the target of a large growth in short interest in December. As of December 15th, there was short interest totaling 27,450 shares, a growth of 102.0% from the November 30th total of 13,586 shares. Based on an average daily trading volume, of 25,799 shares, the short-interest ratio is presently 1.1 days. Approximately 0.0% of the shares of the stock are sold short. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 25,799 shares, the short-interest ratio is presently 1.1 days.
Wall Street Analyst Weigh In
PHAR has been the topic of several research analyst reports. Weiss Ratings restated a “hold (c-)” rating on shares of Pharming Group in a research report on Monday, December 22nd. Wall Street Zen raised Pharming Group to a “strong-buy” rating in a research note on Saturday. Finally, Zacks Research upgraded Pharming Group from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $38.00.
View Our Latest Analysis on PHAR
Pharming Group Price Performance
Shares of PHAR stock traded down $0.29 during trading hours on Friday, hitting $17.80. The stock had a trading volume of 20,818 shares, compared to its average volume of 23,431. The company has a debt-to-equity ratio of 0.35, a current ratio of 3.16 and a quick ratio of 2.39. The stock has a market capitalization of $1.22 billion and a price-to-earnings ratio of -1,778.22. Pharming Group has a one year low of $7.50 and a one year high of $18.30. The stock’s 50-day moving average price is $15.96 and its two-hundred day moving average price is $13.73.
Pharming Group (NASDAQ:PHAR – Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.05. Pharming Group had a return on equity of 0.46% and a net margin of 0.30%.The company had revenue of $97.30 million during the quarter, compared to analyst estimates of $98.22 million. Equities analysts forecast that Pharming Group will post -0.2 EPS for the current year.
Institutional Investors Weigh In On Pharming Group
An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC acquired a new stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 2,979 shares of the company’s stock, valued at approximately $32,000. Hedge funds and other institutional investors own 0.03% of the company’s stock.
Pharming Group Company Profile
Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.
The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.